Retinal protection by changing gene expressions for glaucoma therapy
Project/Area Number |
16K11308
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Ophthalmology
|
Research Institution | Tokyo Metropolitan Institute of Medical Science |
Principal Investigator |
HARADA Chikako 公益財団法人東京都医学総合研究所, 運動・感覚システム研究分野, 研究員 (20435720)
|
Research Collaborator |
HARADA takayuki
NAMEKATA kazuhiko
KAKU gyorei
KIMURA atsuko
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 緑内障 / 神経保護 / 軸索再生 / 遺伝子発現 / 視神経外傷 / 既存薬 / 神経栄養因子 |
Outline of Final Research Achievements |
We demonstrated the neuroprotective effects of existing drugs, such as Rho/ROCK inhibitor eye drops, edaravone used for cerebral infarction, and N-acetylcysteine used as expectorant, and published these findings. In addition, we found that loss of neuritin, one of the trophic factors, increases neural cell death after optic nerve injury. We also found that loss of TrkB, one of the major neurotrophin receptors, induces normal tension glaucoma-like retinal degeneration after 6 months of age.
|
Academic Significance and Societal Importance of the Research Achievements |
緑内障は我が国における最大の失明原因であり、眼圧降下以外の手法による神経保護療法の開発が期待されている。そこで本研究では複数の緑内障モデル動物を用いて、安全性が確立した既存薬による細胞保護療法の可能性を示した。また特定の遺伝子発現の変化が神経細胞の耐性に与える影響を検討して、将来の薬物開発や新たな疾患モデルの開発に道をつけた。
|
Report
(4 results)
Research Products
(35 results)
-
-
-
-
-
-
-
-
[Journal Article] Valproic acid and ASK1 deficiency ameliorate optic neuritis and neurodegeneration in an animal model of multiple sclerosis.2017
Author(s)
Azuchi, Y., Kimura, A., Guo, X., Akiyama, G., Noro, T., Harada, C., Nishigaki, A., Namekata, K., Harada, T.
-
Journal Title
Neuroscience Letters
Volume: 639
Pages: 82-87
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Targeting oxidative stress for treatment of glaucoma and optic neuritis.2017
Author(s)
Kimura, A., Namekata, K., Guo, X., Noro, T., Harada, C., Harada, T.
-
Journal Title
Oxidative Medicine and Cellular Longevity
Volume: 2017
Issue: 1
Pages: 2817252-2817252
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
[Journal Article] Neuroprotection, growth factors and BDNF-TrkB signaling in retinal degeneration.2016
Author(s)
Kimura, A., Namekata, K., Guo, X., Harada, C., Harada, T.
-
Journal Title
International Journal of Molecular Sciences
Volume: 17
Issue: 9
Pages: 1584-1584
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Caloric restriction promotes cell survival in a mouse model of normal tension glaucoma.2016
Author(s)
Guo, X., Kimura, A., Azuchi, Y., Akiyama, G., Noro, T., Harada, C., Namekata, K., Harada, T.
-
Journal Title
Scientific Reports
Volume: 6
Issue: 1
Pages: 33950-33950
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
[Presentation] Spontaneous normal tension glaucoma in aged marmosets.2018
Author(s)
Takayuki Harada, Takahiko Noro, Kazuhiko Namekata, Atsuko Kimura, Nanako Hashimoto, Keiko Moriya-Ito, Xiaoli Guo, Chikako Harada, Tadashi Nakano, Takashi Inoue, Erika Sasaki.
Organizer
8th World Glaucoma Congress
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-